We assessed tumor cell characteristics associated with immune suppression (PD-L1, CD47, and HVEM) or known tumor features associated with response/resistance to daratumumab treatment (expression levels of CD38 and the complement inhibitory proteins CD55 and CD59). Here, CD59 is linked to neoplasm.